Infrared Photobiomodulation in Humans With Epilepsy

Recruiting now · Not applicable

Conditions studied: Drug Resistant Epilepsy

In brief

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Key facts

Study ID

NCT07145489

Run by

Beth Israel Deaconess Medical Center

People needed

13

Starts

2025-11-25

Expected to finish

2027-09-25

Last updated by the study team

2026-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Drug resistant epilepsy
• Age 18 or older
• Average seizure rate of at least 2 seizures per month
• Accurate seizure diary with at least 3 months recorded

You may not qualify if…

• Implanted intracranial neurostimulation device (DBS or RNS)
• Intracranial shunt
• Skin photosensitivity
• Cancer on scalp
• Taking any medication that can cause photosensitivity

Where it is running

• BIDMC — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.